Beyond the Dopamine Ceiling: The Modern Mania Landscape

Research evidence excerpt

Beyond the Dopamine Ceiling: The Modern Mania Landscape

July 15, 2026 Beyond the Dopamine Ceiling: The

Modern Mania Landscape

Kambiz Yazdi

How differentiated mechanisms, tolerability tradeoffs, and regulatory (212) 588-6580 kyazdi@btig.com

precedent set the stage for a disruptor to reshape treatment options in

acute bipolar mania.BIOTECHNOLOGY WHAT YOU SHOULD KNOW: Despite decades of therapeutic innovation, treatment

of acute bipolar mania remains largely dependent on dopamine-modulating

antipsychotics and mood stabilizers developed between 1970 and 2015. While modern

agents have improved tolerability and expanded treatment across multiple phases of

bipolar disorder, meaningful challenges remain including akathisia, metabolic burden,

sedation, orthostatic hypotension and medication adherence. This vacuum in novelINDUSTRY mechanism driven assets continues to be a meaningful commercial opportunity for

agents that can demonstrate robust antimanic efficacy while offering differentiated

safety and tolerability advantages. RAP-219’s TARPγ8-selective mechanism is well-

matched to the neurobiology of acute mania and its selectivity could proveREPORT advantageous to mitigating these unwanted side effects.

Acute mania is one of the most disruptive manifestations of bipolar disorder and

frequently results in psychiatric hospitalization, increased healthcare utilization,

treatment non-compliance and elevated risk of dangerous behavior or legal

involvement.

■ Current treatment of acute bipolar mania revolves around mood stabilizers and

atypical antipsychotics that have been SOC for the past two decades. Most clinical

practice guidelines recommend lithium or divalproex as foundational therapies,

with atypical antipsychotics added in moderate-to-severe episodes or when rapid